TECTONIC THERAPEUTIC, INC. Preferred Stock, Accretion of Redemption Discount
TECTONIC THERAPEUTIC, INC. (TECX) reported Preferred Stock, Accretion of Redemption Discount of $2.24 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-16.
Discontinued › Shareholders' Equity
us-gaap:PreferredStockAccretionOfRedemptionDiscount · last filed 2020-03-16
- TECTONIC THERAPEUTIC, INC. preferred stock, accretion of redemption discount for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. preferred stock, accretion of redemption discount for the quarter ending 2018-09-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. preferred stock, accretion of redemption discount for the quarter ending 2018-06-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. preferred stock, accretion of redemption discount for the quarter ending 2018-03-31 was $2.24M.
- TECTONIC THERAPEUTIC, INC. preferred stock, accretion of redemption discount for fiscal 2018 was $2.24M, a 2538.82% increase from fiscal 2017.
- TECTONIC THERAPEUTIC, INC. preferred stock, accretion of redemption discount for fiscal 2017 was $85.00K.
| Period end | Preferred Stock, Accretion of Redemption Discount 3 month | Preferred Stock, Accretion of Redemption Discount 6 month | Preferred Stock, Accretion of Redemption Discount 9 month | Preferred Stock, Accretion of Redemption Discount 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $0.00 derived: sum of 2 quarters · filed 2020-03-16 | $0.00 derived: sum of 3 quarters · filed 2020-03-16 | $2.24M 10-K · filed 2020-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $2.24M 10-Q · filed 2019-11-07 | $2.28M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $2.24M 10-Q · filed 2019-08-08 | $2.28M derived: sum of 3 quarters · filed 2019-08-08 | $2.28M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $2.24M 10-Q · filed 2019-05-13 | $2.28M derived: sum of 2 quarters · filed 2019-05-13 | $2.28M derived: sum of 3 quarters · filed 2019-05-13 | |
| 2017-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | $38.00K derived: sum of 2 quarters · filed 2019-03-25 | $85.00K 10-K · filed 2019-03-25 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $47.00K 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $47.00K 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |